Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia

We have examined natural killer (NK) cell functionality of 54 B-CLL patients upon in vitro stimulation with interleukin-21 (IL-21), together with the anti-CD20 antibody, rituximab. Upon stimulation with rituximab-coated target cells IFN-gamma production was reduced in patients' NK cells compared to healthy donors', while both natural-and antibody-dependent cytotoxicity (ADCC) was normal. Following additional stimulation with IL-21, IFN-gamma production, natural cytotoxicity and ADCC were significantly augmented in patients. A complete restoration of IFN-gamma production, however, required the depletion of malignant cells prior to stimulation. Collectively, our data show that NK cells of B-CLL patients are reversibly inhibited, but that their functionality can be normalized by stimulation with IL-21 and when inhibitory effects of the malignant B-CLL cells are eliminated by depletion. (C) 2011 Elsevier Ltd. All rights reserved.